Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials in 2021 The Association of...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
Rescue studies are a particular point of strength at Agilex Biolabs, where the bioanalytical experts are driven to solve challenges presented by what we call “the weird and wonderful”.
On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development” in BioSpectrum Asia Excellence Awards.
Agilex Biolabs, the leading bioanalytical laboratory supporting Australian clinical trials, has established its first satellite processing unit staffed with highly specialised technicians on the fifth floor of the CMAX Clinical Research facility in Adelaide, SA.
Agilex Biolabs has expanded its capacity to better serve the biotech, pharmaceutical and animal health industry with the opening of its new in-vivo testing facility.
Circulating tumor DNA (ctDNA) is tumor-deriver fragmented DNA which originates either directly from the tumor or from circulating tumor cells.
Immunogenicity assessment of biotherapeutics is a regulatory requirement and key parameter for assessing the safety and efficacy of a drug candidate.
Immunogenicity assessment is a critical safety attribute for biotherapeutics undergoing clinical development.
Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs Kurt Sales as Chief Scientific Officer will lead future...